L

Lineage Cell Therapeutics
D

LCTX

0.57000
USD
-0.01
(-2.55%)
مغلق
حجم التداول
113,554
الربح لكل سهم
-0
العائد الربحي
-
P/E
-6
حجم السوق
125,637,306
أصول ذات صلة
    A
    ADVM
    -0.40000
    (-5.51%)
    6.86000 USD
    A
    ATHX
    0.00290
    (2.96%)
    0.10100 USD
    L
    LGND
    -3.790
    (-3.28%)
    111.690 USD
    M
    MESO
    -1.280
    (-11.32%)
    10.030 USD
    P
    PSTV
    -0.08000
    (-6.35%)
    1.18000 USD
    Q
    QURE
    -0.55000
    (-8.14%)
    6.21000 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    المزيد
الأخبار

العنوان: Lineage Cell Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.